Turnstone Biologics is a clinical-stage biotech pioneering next-generation cancer immunotherapies using two core platforms: a proprietary vaccinia-based oncolytic virus platform and a novel TIL therapy platform. Its lead oncolytic candidate, RIVAL-01/TAK-605, is in the dose-escalation stage of a Phase 1/2a trial conducted in collaboration with Takeda. The vaccinia platform is engineered for enhanced immune stimulation, tumor cell selectivity, large transgene carrying capacity, and both intratumoral and intravenous delivery. The TIL program is designed to enrich for the most relevant tumor-reactive T-cells, preserve broad antigen diversity, and minimize time to treatment, with the lead TIL candidate TIDAL-01 expected to enter the clinic by early 2022. Proceeds from the recently completed financing will be used to advance programs across both platforms. The company states its goal is to extend the benefit of these immunotherapies to a wider range of solid tumor patients underserved by current options. Turnstone Biologics is developing a first‑in‑class oncolytic vaccine platform that functions both as a tumor‑destroying oncolytic agent and as an immune‑stimulating vaccine directed at specific cancer antigens. Its most advanced product is an engineered oncolytic Maraba virus expressing MAGEA3, currently in a Phase I/II monotherapy trial. Completion of that trial is expected in 2017, and Turnstone plans a Phase I/II combination trial with an approved checkpoint inhibitor in NSCLC later this year. Two additional Maraba programs expressing different tumor antigens are expected to enter clinical trials by the end of next year. The company is also advancing neoantigen‑based personalized cancer vaccines and new oncolytic virus development. Turnstone raised a $41.4M Series B to support completion of the ongoing trial and to fund three additional clinical programs. Turnstone Biologics develops novel oncolytic viral immunotherapies aimed at treating advanced and metastatic solid tumours. Its first programs are currently in Phase I/II clinical trials in patients with advanced or metastatic solid tumours. The company is also developing additional oncolytic virus strategies and immunotherapy combination treatments. Turnstone was co-founded by Drs. John Bell, Brian Lichty and David Stojdl. The company is led by CEO Sammy J. Farah, PhD, MBA, and CTO Brian D. Lichty, PhD—appointments enabled by recent investment. Turnstone completed an $11.3M Series A and has follow-on capital committed in excess of $20.0M.

Total raised

$133M

Funding rounds

3

Latest round

Series D

Latest activity

Jul 2021